PYROXD2

Across TCGA pan-cancer cohorts, PYROXD2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PYROXD2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where PYROXD2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PYROXD2 is over-expressed in tumor, although a few such as LSCC and HNSC show the opposite, repressed pattern.

LSCC, HNSC, and COAD are the cancer types where PYROXD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PYROXD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	−0.861	<.001	8	view →
HNSC	All	IV	−0.811	<.001	8	view →
COAD	Female	All	−1.281	<.001	6	view →
CCRCC	Male	All	−0.482	<.001	6	view →
LUAD	Male	All	−0.424	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PYROXD2–LSCC

Open the LSCC breakdown →